SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event
(Exact name of registrant as specified in its charter)
(State or other
jurisdiction of incorporation)
|(Address of Principal Executive Offices) (Zip Code)|
|Registrant's telephone number, including area code:(|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol||Name of each exchange on which registered|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company
|If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.||¨|
|Item 5.02.||Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.|
On December 7, 2020, Michael C. MacDonald resigned, effective immediately, as a director and Chairman of the Board of Directors (the “Board”) of Medifast, Inc. (the “Company”). Mr. MacDonald’s resignation did not involve any disagreement with management or the Board related to the Company’s operations, policies or practices.
To fill the vacancy created by Mr. MacDonald’s resignation, on December 10, 2020, the Board appointed Mr. Daniel Chard, Chief Executive Officer and current director of the Company, as Executive Chairman of the Board. Mr. Chard has no family relationship with any of the executive officers or directors of the Company. There are no arrangements or understandings between Mr. Chard and any other person pursuant to which he is being appointed as the Executive Chairman of the Board.
|Item 8.01.||Other Events.|
On December 10, 2020, the Company issued a press release announcing the declaration of a cash dividend by the Board. The full text of the press release is attached as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
|Item 9.01.||Financial Statements and Exhibits.|
|99.1||Press release dated December 10, 2020 titled “Medifast, Inc. Announces Quarterly Dividend”|
|104.1||Cover Page Interactive Data File (embedded within the Inline XBRLDocument)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|By:||/s/ James P. Maloney|
James P. Maloney
Chief Financial Officer
|Dated: December 10, 2020|